Amniox Medical touts reimbursement wins, extended cryo lifespan

Amniox Medical this month touted a reimbursement win from Palmetto Medicare as well as a 2-year cryopreserved lifespan for its Neox Cord 1k as it attempts to position itself as a market leader in wound care. The Atlanta, Ga.-based company said that Palmetto Medicare recently included Amniox’s Neox Cord 1k and Neox 100 would allografts in a new skin substitute reimbursement policy, growing the product reach to more than 70% of Medicare patients. The policy shift will allow for skin substitute applications that are medically necessary and follow proper billing guidelines, the company said. “We now have coverage for virtually 70% of the coverage Medicare allows, with our most recent decisions being Palmetto and WPS. What we’ve done is, through our direct sales organization, we’ve place our people in the areas where we have coverage to grow our direct sales organization,” CEO Thomas Dugan told MassDevice.com in an interview. Dugan said that the company is focused on wound care, seeing it as an under-penetrated market with room for growth.  But the company isn’t limiting itself to only wound care, and is using independent sales groups to expand into the orthopedic sphere. “In orthopedics we focus on foot and ankle – we believe we’re the market leader in foot and ankle. It’s where we started, it’s been our heritage and we’re doing very well in that market. Our products work well with foot and ankle surgery – if you think about it,...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Regenerative Medicine Amniox Medical Source Type: news